Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Decitabine + R-CHOP for Initial Treatment of EBV+ DLBCL
NCT07348575Phase 3Enrolling by invitation
- Sponsor
- The Second Affiliated Hospital of Nanchang University
- Start
- Jul 2024
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of decitabine in diffuse large B-cell lymphoma (DLBCL), sponsored by The Second Affiliated Hospital of Nanchang University. Started Jul 2024; status: enrolling by invitation.
02
Drugs
decitabine
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT07348575.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07348575.